Focus on Advanced NSCLC: Expert Insights and Strategies for Refining Patient Care
  • Program Overview
    Focus on Advanced NSCLC: Expert Insights and Strategies for Refining Patient Care
    Explore key issues in the management of advanced NSCLC in this educational program designed to keep you abreast of rapidly evolving treatment practices. Gain expert insights on new developments as they emerge with the CME/CE-certified interactive modules, short expert commentaries, and the Interactive Decision Support Tool that will let you compare your treatment choices for specific patient scenarios in advanced NSCLC with those of 5 experts.
  • Featured content
    In this interactive, CME/CE-certified module, Alice Shaw, MD, PhD, provides her perspective on optimizing treatment strategies for advanced-stage ALK and ROS1 rearrangement–positive NSCLC.
  • Checkpoint inhibitor therapy is now approved for newly diagnosed metastatic NSCLC. Naiyer Rizvi, MD, discusses the latest clinical data from ESMO 2016 supporting this landmark change in advanced NSCLC management.
    Date Posted: 10/27/2016
  • Featured content
    In this interactive, CME/CE-certified module, Suresh S. Ramalingam, MD, provides expert perspective on optimizing treatment strategies for advanced-stage squamous NSCLC.
  • Featured content
    How long should we continue patients with NSCLC on immune checkpoint inhibitors? H. Jack West, MD, shares his thoughts on this clinically important issue.
    Date Posted: 9/30/2016
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

9 of 9 Shown
  • Clinical Focus cme-icon ce-icon

    Evidence-Based Treatment for ALK and ROS1 Rearrangement–Positive NSCLC

    In this interactive, CME/CE-certified module, Alice Shaw, MD, PhD, provides her perspective on optimizing treatment strategies for advanced-stage ALK and ROS1 rearrangement–positive NSCLC.
    Faculty: Alice Shaw MD, PhD
    Released: 12/28/2016
  • Evidence-Based Treatment for ALK and ROS1 Rearrangement–Positive NSCLC

    In this downloadable slideset, Alice T. Shaw, MD, PhD, highlights key studies for optimizing the management of patients with advanced-stage ALK and ROS1 rearrangement–positive NSCLC.
    Date Posted: 12/22/2016
  • Atezolizumab: A New Treatment Option for Progressive Metastatic NSCLC

    Melissa L. Johnson MD - 12/20/2016 1 comment / Last Comment: 12/21/2016
    There is now a third checkpoint inhibitor approved for metastatic NSCLC. Melissa L. Johnson, MD, discusses the latest clinical data from ESMO 2016 that led to the FDA approval of atezolizumab for advanced NSCLC that has progressed on previous platinum-based chemotherapy.
  • Clinical Dilemma: A Patient With a Diagnosis of Stage IV NSCLC-NOS Is Referred to You for a Second Opinion

    Leora Horn MD, MSc, FRCPC - 11/21/2016 2 comments / Last Comment: 11/28/2016
    In the age of targeted therapies and immune checkpoint inhibition, Leora Horn, MD, MSc, FRCPC, discusses the importance of avoiding diagnoses of lung cancer–not otherwise specified in the optimal treatment of patients with newly diagnosed, advanced NSCLC.
  • First-line Checkpoint Inhibitor Therapy in Metastatic NSCLC: A New Option for Our Patients

    Naiyer Rizvi MD - 10/27/2016 3 comments / Last Comment: 12/12/2016
    Checkpoint inhibitor therapy is now approved for newly diagnosed metastatic NSCLC. Naiyer Rizvi, MD, discusses the latest clinical data from ESMO 2016 supporting this landmark change in advanced NSCLC management.
  • Clinical Focus cme-icon ce-icon

    Evidence-Based Strategies for Challenging Squamous NSCLC Cases

    In this interactive, CME/CE-certified module, Suresh S. Ramalingam, MD, provides expert perspective on optimizing treatment strategies for advanced-stage squamous NSCLC.
    Faculty: Suresh S. Ramalingam MD
    Released: 10/6/2016
  • Evidence-Based Strategies for Challenging Squamous NSCLC Cases

    In this downloadable slideset, Suresh S. Ramalingam, MD, highlights key studies for optimizing the management of patients with advanced-stage squamous NSCLC.
    Date Posted: 10/6/2016
  • Immune Checkpoint Blockade in Advanced Lung Cancer Patients: Optimizing Treatment Duration

    H. Jack West MD - 9/30/2016 5 comments / Last Comment: 10/24/2016
    How long should we continue patients with NSCLC on immune checkpoint inhibitors? H. Jack West, MD, shares his thoughts on this clinically important issue.
  • An Interactive Online Tool Featuring Expert Recommendations for Advanced NSCLC

    David R. Gandara MD - 8/5/2016 6 comments / Last Comment: 10/23/2016
    Are you interested in seeing treatment recommendations from 5 lung cancer experts?
9 of 9 Shown
Show 0 More
Loading...